Blueprint Medicines (BPMC) PT Raised to $147 at Goldman Sachs, Following Earnings
- Wall Street ends sharply lower in broad sell-off
- China Property Titan Evergrande (EGRNF) Collapses to 11-Year Lows, Analysts Wary of Domino Effect
- Apple (AAPL) iPhone 13 Has Strong Start with Positive Mix Skew - JP Morgan
- Lennar (LEN) Falls as Reported Q3 Revenue Beats, EPS Slightly Missed Estimates
- Royal Dutch Shell to Sell its Permian Business to ConocoPhillips (COP) for $9.5 Billion Cash
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
Goldman Sachs analyst Salveen Richter raised the price target on Blueprint Medicines (NASDAQ: BPMC) to $147.00 (from $144.00) while maintaining a Buy rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- D.R. Horton (DHI) PT Lowered to $109 at Goldman Sachs, Following Guidance Update
- Redrow PLC (RDW:LN) (RDWWF) PT Raised to GBP9 at Berenberg
- Anglo American PLC (AAL:LN) (NGLOY) PT Lowered to GBP39 at Berenberg
Create E-mail Alert Related CategoriesAnalyst PT Change
Related EntitiesGoldman Sachs, Earnings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!